Lack of Evidence for Treatment Effects Based on Disease Severity in Severe Sepsis
Author Information
Author(s): Williams L. Macias, David R. Nelson, Mark Williams, Rekha Garg, Jonathan Janes, Andreas Sashegyi
Primary Institution: Lilly Research Laboratories
Hypothesis
Does the mortality risk of patients with severe sepsis affect the relative treatment effect of investigational agents?
Conclusion
The review found no evidence that the mortality risk alters the treatment effect of agents used for severe sepsis.
Supporting Evidence
- Three studies showed a statistically significant reduction in 28-day all-cause mortality.
- Control group mortality rates ranged from 31% to 61% across studies.
- Interventions with anticoagulant or anti-inflammatory activity were not harmful in patients with less coagulopathy or inflammation.
Takeaway
This study looked at whether the severity of illness changes how well treatments work for severe sepsis, and it found that it doesn't.
Methodology
A systematic review of phase III, randomized, placebo-controlled trials in adult patients with severe sepsis or septic shock.
Potential Biases
Post hoc subgroup analyses may introduce bias as they can highlight beneficial effects in certain strata while masking unfavorable effects in others.
Limitations
The analysis is based on published literature, which may be subject to publication bias.
Participant Demographics
Adult patients with severe sepsis or septic shock.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website